Tag: Cancer: Stomach
H. Pylori Infection Must Be Wiped Out to Cut Gastric Cancer Risk
Risk for gastric cancer tied to H. pylori infection higher in blacks, Asians, Hispanics/Latinos
Four Studies Look at Global Burden of Digestive Diseases
Global burdens of colorectal, pancreatic, stomach cancers and inflammatory bowel disease examined
H. Pylori Treatment May Reduce Gastric Cancer Incidence, Death
Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation
T2DM Increases Gastric Cancer Risk After H. Pylori Eradication
Targeted screening should be considered in high-risk patients following H. pylori eradication therapy
ASCO: Low-Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival
Pembrolizumab Not Better Than PTX for Advanced Gastric Cancer
Survival no better with second-line pembrolizumab than paclitaxel for gastric, gastro-esophageal cancer
H. Pylori Treatment Tied to Lower Metachronous Gastric Cancer Risk
Those treated after early CA also had improvement in atrophy grade at gastric corpus lesser curvature
Disparities Seen in Gastric Cancer Patients’ Receipt of Pre-Op Chemo
Racial, ethnic disparities in treatment also affect disparities in overall survival
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is approved to treat HER2+ breast and gastric or gastroesophageal junction adenocarcinoma cancers
